Valvular & structural heart diseaseGuideline or statement
Management of patients with transvalvular right ventricular leads undergoing transcatheter tricuspid valve interventions: a scientific statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC endorsed by the Heart Rhythm Society, the Asian Pacific Heart Rhythm Society and the Canadian Heart Rhythm Society
- Scientific statement
Scope
As issued by the authors
Reviews the scientific evidence to inform Heart Team discussions on managing patients with a PPM or implantable cardioverter-defibrillator (ICD) who are scheduled for or have undergone transcatheter tricuspid valve intervention (TTVI); up to one-third of TTVI referrals have a transvalvular lead, with risk of lead jailing or damage
Original publication
Management of patients with transvalvular right ventricular leads undergoing transcatheter tricuspid valve interventions: a scientific statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC endorsed by the Heart Rhythm Society, the Asian Pacific Heart Rhythm Society and the Canadian Heart Rhythm Society. Europace. Published 31 March 2025. doi:10.1093/europace/euaf061
Summarised from the published abstract; every number is checked against it